PMID- 22631452
OWN - NLM
STAT- MEDLINE
DCOM- 20121212
LR  - 20220330
IS  - 1460-2202 (Electronic)
IS  - 0271-3683 (Linking)
VI  - 37
IP  - 8
DP  - 2012 Aug
TI  - Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: 
      a systematic review and meta-analysis of randomized clinical control trials.
PG  - 661-70
LID - 10.3109/02713683.2012.675616 [doi]
AB  - PURPOSE: To evaluate the therapeutic effect and safety of intravitreal 
      ranibizumab (RBZ) or RBZ combined with focal/grid laser in diabetic macular edema 
      (DME). DESIGN: Systematic review of randomized clinical control trials (RCCTs) 
      comparing RBZ or RBZ combined with focal/grid laser to non-drug control or 
      focal/grid laser in DME was performed. METHODS: The RCCTs in Cochrane Central 
      Register of Controlled Trials, PUBMED, EMBASE, the metaRegister of Controlled 
      Trials, and ClinicalTrials.gov were included. The means and standard deviations 
      of change from baseline in best-corrected visual acuity (BCVA) and central 
      macular thickness (CMT) were extracted at 12 or 24 months. Data regarding 
      complications were collected. The Review Manager 5.1.2 was used. RESULTS: Four 
      trials with a total of 1313 DME patients were included. Our analysis showed that 
      intravitreal RBZ appeared to be superior to non-drug therapy in reducing CMT (12 
      months, p = 0.02), and improving BCVA with statistical significance (12 months, p 
      = 0.0003). RBZ combined with focal/grid laser experienced statistically 
      significant reduction in CMT (12 months, p = 0.01), and improvement in BCVA (12 
      months, p < 0.00001; 24 months, p = 0.007) compared with focal/grid laser. The 
      incidence of adverse events (AEs) had no statistical difference between RBZ 
      monotherapy or RBZ combined with laser and the noninvasive interventions. The 
      improvement in BCVA and CMT from the RBZ and RBZ plus laser arms both had no 
      statistically significant difference. While the mean number of intravitreal 
      injections needed was lower in RBZ plus laser arm than RBZ arm at the end of 24 
      months. CONCLUSIONS: Our analysis shows that RBZ and RBZ combined with focal/grid 
      laser is more advantageous than non-drug treatment or focal/grid laser in 
      reducing CMT and improving BCVA in DME during 12 and 24 months follow-up period 
      and can be well tolerated based on the safety assessment. Intravitreal RBZ may be 
      equivalent to RBZ combined with focal/grid laser.
FAU - Wang, Haiyan
AU  - Wang H
AD  - Department of Ophthalmology, Shanghai First People's Hospital, Affiliate of 
      Shanghai Jiaotong University, Shanghai, PR China.
FAU - Sun, Xiaodong
AU  - Sun X
FAU - Liu, Kun
AU  - Liu K
FAU - Xu, Xun
AU  - Xu X
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20120525
PL  - England
TA  - Curr Eye Res
JT  - Current eye research
JID - 8104312
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/*administration & dosage
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage
MH  - Diabetic Retinopathy/*drug therapy
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Ranibizumab
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
EDAT- 2012/05/29 06:00
MHDA- 2012/12/13 06:00
CRDT- 2012/05/29 06:00
PHST- 2012/05/29 06:00 [entrez]
PHST- 2012/05/29 06:00 [pubmed]
PHST- 2012/12/13 06:00 [medline]
AID - 10.3109/02713683.2012.675616 [doi]
PST - ppublish
SO  - Curr Eye Res. 2012 Aug;37(8):661-70. doi: 10.3109/02713683.2012.675616. Epub 2012 
      May 25.